Meeting Provided a Clear Path for Planned Phase 3b Trial Special Protocol Assessment A Special Protocol Assessment (SPA) is a process in which drug developers may ask to meet with the FDA to reach ...
BrainStorm just announced that it has secured an FDA advisory committee vote for treatment candidate NurOwn for the treatment of ALS. NurOwn’s results on biomarker NfL in combination with other ...
NEW YORK, Sept. 24, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two ...
NEW YORK, April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ALS ...
BrainStorm (BCLI) announced the presentation of two posters featuring NurOwn at the 2024 Annual Northeastern Amyotrophic Lateral Sclerosis Consortium, or NEALS, Meeting, which took place virtually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results